Contents
pdf Download PDF pdf Download XML pdf Download Full Text
3 Views
5 Downloads
Share this article
Research Article | | Volume 15 Issue 9 (September, 2026) | Pages 147 - 153

Intracoronary Autologous Bone Marrow-Derived Cell Therapy in Acute Myocardial Infarction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

1
Department of Laboratory Medicine, Faculty of Applied Medical, Al-Baha University, Saudi Arabia
Under a Creative Commons license
Open Access
Received
March 25, 2026
Revised
June 5, 2026
Accepted
Sept. 13, 2026
Published
Oct. 5, 2026

Abstract

Objectives: Intracoronary autologous bone marrow-derived cell therapy has been proposed to enhance myocardial repair after Acute Myocardial Infarction (AMI), but the included cell products and trial designs vary considerably across the RCT literature. Methods: PubMed, Embase, Cochrane CENTRAL, Scopus and Web of Science were searched from inception to 2025 for randomized controlled trials of intracoronary autologous bone marrow-derived cell therapy (Bone Marrow Mononuclear Cells [BMMNC], BMMNC/peripheral blood mononuclear cell mixtures, or selected CD34+/BMMNC combinations) versus standard care following AMI, reporting change in Left Ventricular Ejection Fraction (LVEF). Study selection, data extraction and Risk-of-Bias assessment (Cochrane RoB 2.0) were performed by a single reviewer. Random-effects meta-analysis (DerSimonian-Laird, with a Paule-Mandel estimator as a sensitivity analysis) was used to pool the Mean Difference (MD) in LVEF. This review was not prospectively registered. Results: Six RCTs (738 patients: 411 cell therapy, 327 control) met inclusion criteria. Pooled LVEF change favored cell therapy (MD +1.60%; 95% CI 0.72-2.47; I² = 0%), a result unchanged under the Paule-Mandel sensitivity estimator. No significant effects were observed for all-cause mortality (RR 0.94; 95% CI 0.71-1.25), major adverse cardiac events (MACE; RR 0.89; 95% CI 0.68-1.16), or infarct size (MD-1.5%; 95% CI-3.8 to 0.8). Certainty of evidence, graded by GRADE, ranged from low to very low across outcomes, driven primarily by risk of bias and imprecision. Conclusion: Intracoronary autologous bone marrow-derived cell therapy produces a small, statistically significant improvement in LVEF after AMI, without a demonstrated effect on mortality, MACE, or infarct size in this dataset. The clinical relevance of the LVEF effect remains uncertain and the certainty of the underlying evidence is low.

Keywords
Stem Cell Therapy, Acute Myocardial Infarction, Bone Marrow Mononuclear Cells, Left Ventricular Ejection Fraction, Cardiac Regeneration, Meta-Analysis
Recommended Articles
Research Article

Prevalence of Fibromyalgia and Its Associated Factors in Saudi Arabia: An Updated Systematic Review

Published: 05/10/2026
pdf Download PDF
Research Article

Clinical, Biochemical and Nrf2-Keap1-Related Outcomes of Silver Nanoparticle-Adjunct Therapy in Adults with Osteoarthritis or Rheumatoid Arthritis: A Prospective Comparative Study

...
Published: 05/10/2026
pdf Download PDF
Research Article

Characterization of gyrA and gyrB Genes in Mycobacterium Tuberculosis Clinical Isolates from Mosul, Iraq

...
Published: 05/10/2026
pdf Download PDF
Research Article

Assessment of Modifiable and Non-Modifiable Risk Factors for Knee Osteoarthritis Over the Lifespan and Their Association with Poor Lifestyle: Comparative Study

...
Published: 05/10/2026
pdf Download PDF
Copyright © Journal of Pioneering Medical Sciences until unless otherwise.